American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
Allogeneic transplantation
Autologous transplantation
CAR T cell
Cellular therapy
Consensus
Mantle cell lymphoma
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
01
03
2021
accepted:
01
03
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
15
10
2021
Statut:
ppublish
Résumé
Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
Identifiants
pubmed: 34452722
pii: S2666-6367(21)00744-2
doi: 10.1016/j.jtct.2021.03.001
pmc: PMC8447221
mid: NIHMS1739419
pii:
doi:
Types de publication
Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
720-728Subventions
Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069197
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130388
Pays : United States
Organisme : NHLBI NIH HHS
ID : OT3 HL147741
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc. All rights reserved.
Références
JAMA Oncol. 2019 May 01;5(5):715-722
pubmed: 30816957
J Clin Oncol. 2009 Dec 20;27(36):6101-8
pubmed: 19917845
Ann Hematol. 2014 Sep;93(9):1587-97
pubmed: 24782119
J Clin Oncol. 2014 Feb 1;32(4):273-81
pubmed: 24344210
Br J Haematol. 2019 Mar;184(6):1006-1010
pubmed: 30537212
J Clin Oncol. 2014 Jul 1;32(19):2100-8
pubmed: 24799487
Br J Haematol. 2012 Aug;158(3):355-62
pubmed: 22640180
Blood. 2005 Apr 1;105(7):2677-84
pubmed: 15591112
Lancet. 2016 Aug 6;388(10044):565-75
pubmed: 27313086
Blood. 2018 Jan 25;131(4):417-420
pubmed: 29196411
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
Blood. 2004 Dec 1;104(12):3535-42
pubmed: 15304387
Health Technol Assess. 1998;2(3):i-iv, 1-88
pubmed: 9561895
J Clin Oncol. 2003 Dec 1;21(23):4407-12
pubmed: 14645431
Leukemia. 2015 Feb;29(2):464-73
pubmed: 25034148
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
J Clin Oncol. 2019 Feb 20;37(6):471-480
pubmed: 30615550
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
J Clin Oncol. 2009 Mar 10;27(8):1209-13
pubmed: 19188674
N Engl J Med. 2017 Sep 28;377(13):1250-1260
pubmed: 28953447
Blood. 2017 Oct 26;130(17):1903-1910
pubmed: 28819011
J Clin Oncol. 2014 May 1;32(13):1338-46
pubmed: 24687837
Blood. 2012 Mar 1;119(9):2093-9
pubmed: 22234679
Ther Adv Hematol. 2011 Feb;2(1):5-10
pubmed: 23556071
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919
Lancet Haematol. 2018 Mar;5(3):e109-e116
pubmed: 29396091
Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017
pubmed: 32717431
Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31
pubmed: 23333532
J Clin Oncol. 2012 Sep 1;30(25):3136-40
pubmed: 22778311
Curr Oncol. 2019 Apr;26(2):e233-e240
pubmed: 31043832
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Br J Haematol. 2008 Feb;140(4):385-93
pubmed: 18162124